
Challenges and opportunities for innovation in Endometriosis with Dr. Liliane Brunner Halbach
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of Scailyte’s Endometriosis Awareness Series, where Cinzia Donato interviews Dr. Liliane Brunner Halbach on the “Challenges and opportunities for innovation in endometriosis”.
Dr. Liliane Halbach is an experienced healthcare expert with 20+ years of global experience in drug research and development, global product strategy, and business development. With a MSc in Pharmacy and a PhD in Pharmacology from the University of Basel, Switzerland, she has worked in different roles in headquarters and affiliates of Novartis, Roche, and AstraZeneca in Switzerland, Spain, the US, and Singapore.
In addition to her work in the pharmaceutical industry, Dr. Liliane Halbach has been involved with SPARK, a mentoring program that helps researchers bring ideas to a proof-of-concept stage, since 2012, and now leads SPARK Zurich. Two years ago, she joined the Artemis group, a team of experts from VC and Pharma with the goal to bring more innovation to women’s health. After two years of talking to stakeholders and analyzing the gaps, the group founded Artemis Women’s Health Foundation in February 2023 to connect the ecosystem of investors with innovators and find solutions to the issues observed in women’s health.
In this episode, Dr. Liliane Halbach shares her insights on the challenges and opportunities for innovation in endometriosis. Don’t miss out on this exciting conversation and join us to learn more about the latest developments in the field of endometriosis research and innovation.
About Scailyte
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets.
Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.
Recent News
Recent News
Future Labs Live 2023
Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...
Recent News
The psychological and economic impact of endometriosis
We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...
Recent News
Jan Lichtenberg joins Scailyte's Board of Directors
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...
Recent News
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...
Recent News
Swiss Biotech Day 2023
Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...
Recent News
Women's Health Innovation Summit
Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...
Recent News
ISCT 2023
Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...
Future Labs Live 2023
Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...
Recent News
The psychological and economic impact of endometriosis
We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...
Jan Lichtenberg joins Scailyte's Board of Directors
Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...
Recent News
Challenges and opportunities for innovation in Endometriosis
Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...
Swiss Biotech Day 2023
Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...
Recent News
Deciphering Disease Mechanisms Through Functional Genomics
Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...
Women's Health Innovation Summit
Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...